Ecies-specific variations (38) that have complicated development of this class of adjuvants.
Ecies-specific differences (38) that have difficult development of this class of adjuvants. Nonetheless, TLR9 agonists are becoming evaluated within the later stages of clinical development for infectious disease and allergy…